UPC APP 13067/2025

—·EP3175863: VARIANTS OF C-TYPE NATRIURETIC PEPTIDE

Verfahrensdetails: Status
—
Verfahrensart
Vorbescheid
Kategorie
Vorab-Einrede
Parteien: Kläger
BioMarin Pharmaceutical Inc.
Vertreter: Christian Paul (Jones Day); Tobias Mandler (Jones Day); Pascal Grandé (Jones Day); Jason Raeburn (Paul Hastings); Alex Morgan (Paul Hastings)
Beklagte
Ascendis Pharma A/S
Ascendis Pharma Growth Disorders A/S
Vertreter: Agathe Michel-De Cazotte (Carpmaels & Ransford); Anna Leathley (Carpmaels & Ransford); Daniel Wiese (Carpmaels & Ransford)
Division: Munich LD
Richter: Matthias Zigann · Presiding judge and judge-rapporteur
Technology: Biotechnology
Sprache: —
Erste Entscheidung: 2. Apr. 2025

Entscheidungen

2025-04-02
ZuständigkeitPreliminary objection
The Munich Local Division rejected Ascendis Pharma's preliminary objection to jurisdiction in the infringement action brought by BioMarin Pharmaceutical concerning EP 3 175 863 (C-Type Natriuretic Peptide variants for achondroplasia treatment). The court found that the opt-out withdrawal was effective and that sufficient acts of infringement were alleged in Germany.
Rechtsfragen:Preliminary objection to jurisdictionOpt-out withdrawalActs of infringement in GermanyAchondroplasia treatmentTransCon CNP

Dokumente